EGFR and non-small cell lung carcinoma: In our study, the median PFS of 1G or 2G generation EGFR-TKI was 11.1 months (95% CI: 7.2–15.0), and the median OS was 25.6 months (95% CI: 18.2–33.0) in patients with uncommon EGFR mutant-positive NSCLC.